

# Supplementary Materials: Sorafenib with Transarterial Chemoembolization Achieves Improved Survival vs. Sorafenib Alone in Advanced Hepatocellular Carcinoma: A Nationwide Population-Based Cohort Study

Victor C. Kok, Yu-Ching Chen, Yang-Yuan Chen, Yu-Chieh Su, Ming-Chang Ku, Jung-Tsung Kuo and Go J. Yoshida

**Table S1.** STROBE Statement—Checklist of items that should be included in reports of cohort studies.

Item	Item No	Recommendation	Where Can Be Found
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	P. 3
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	P. 3
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	P. 4,5,6
Objectives	3	State specific objectives, including any prespecified hypotheses	P. 6
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	P. 6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	P. 6-10
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	P. 7,8,9
		(b) For matched studies, give matching criteria and number of exposed and unexposed	P. 9
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	P. 7,8
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	P. 7,8,9
Bias	9	Describe any efforts to address potential sources of bias	P. 9,10,11
Study size	10	Explain how the study size was arrived at	P. 8, Fig. 1
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	P. 9,10,11
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	P. 10, 11
		(b) Describe any methods used to examine subgroups and interactions	P. 11
		(c) Explain how missing data were addressed	No missing data
		(d) If applicable, explain how loss to follow-up was addressed	No L.T.F.
		(e) Describe any sensitivity analyses	Table S1
<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Fig. 1
		(b) Give reasons for non-participation at each stage	Fig. 1
		(c) Consider use of a flow diagram	Fig. 1
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Table 1
		(b) Indicate number of participants with missing data for each variable of interest	Table 1
		(c) Summarise follow-up time (eg, average and total amount)	Table 2
Outcome data	15*	Report numbers of outcome events or summary measures over time	Table 2
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Table 2, Table 3, Fig. 2, Fig. 3
		(b) Report category boundaries when continuous variables were categorized	Table 1
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	P. 12, 13

Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Fig. 3, Table S1
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	P. 14
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	P. 16
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	P. 14, 15
Generalisability	21	Discuss the generalisability (external validity) of the study results	P. 14, 15
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	P. 2

\* Give information separately for exposed and unexposed groups. **Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.



© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).